Graft vs Host Disease - 22 Studies Found
| Active, not recruiting |
: A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease : Graft vs Host Disease : 2012-10-02 : Drug: Alpha-1-Antitrypsin (AAT) AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) |
| Completed |
: Cyclosporine Implant for Ocular Graft-Versus-Host Disease : Graft Vs Host Disease : 2005-01-29 : Drug: Subconjunctival Cyclosporine Implant |
| Completed |
: A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease : Graft vs Host Disease : 2015-03-01 : Biological: Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease |
| Terminated |
: A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients : Graft vs Host Disease : 2013-10-23 :
|
| Completed |
: Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease : Graft vs Host Disease : 2005-08-26 : Drug: Rituximab Given once weekly for 4 weeks followed by a 4 week observation therapy. |
| Terminated |
: Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients : Graft vs Host Disease : 2011-01-23 : Drug: Itraconazole 200mg bid, oral solution, until a dose of prednisone was tapered to 10mg/day in case |
| Completed |
: Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease : Graft vs Host Disease : 2010-01-04 : Drug: Alemtuzumab and rituximab Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) R |
| Completed |
: Extracorporeal Photopheresis to Treat Chronic Graft-Versus-Host Disease : Graft vs Host Disease : 2002-11-07 : Procedure: Extracorporeal Photopheresis |
| Completed |
: Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease : Graft vs Host Disease : 2006-10-20 :
|
| Recruiting |
: A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease : Graft vs Host Disease : 2016-07-20 : Drug: KD025 Other Name: SLx-2119 |